| Series D, 4/09 Merck Serono Ventures 5AM Ventures Aravis Ventures CMEA Capital Maverick Capital Versant Ventures Tavistock Life Sciences | $10M |
Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties.
